Immunovant

Immunovant is a clinical-stage biopharmaceutical company dedicated to providing patients with normal lives by addressing autoimmune diseases. Their investigational product candidate, IMVT-1401 (previously known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). They believe that this product has the potential to address various IgG-mediated autoimmune diseases through subcutaneous administration.